VHIO’s seeks a Fellowship in Breast Cancer Unit
Application deadline: 31/01/2020
Number of vacancies: 1
We seek 1 highly motivated fellow to work in clinical and translational research at our Breast Cancer Unit located at the Vall d’Hebron University Hospital (HUVH – Vall d´Hebron Barcelona Hospital Campus). Mentored by a Senior Consultant of our Unit, the successful candidate will be involved in early phase and proof-of-concept, biomarker-driven phase II clinical studies -with particular focus on immuno and immunotherapy combinations and PI3K/AKT/mTOR inhibitors- molecular prescreening activities (in tumor tissue and liquid biopsies), as well as our team’s translational projects. Development of investigator-initiated trials and projects will be highly encouraged, as well as collaborative research with other VHIO groups and external collaborators.
The duration of the Fellowship will be 1-2 years based on prior experience, with the possibility of extending contract upon review of professional merits and performance.
The selection of the successful candidate is envisaged December 2019. The appointed fellow will be expected to join our Unit by the end of January 2020 at the very latest.
The successful candidate must be Spanish or from another EU country, with Board Certification in Medical Oncology. Prior experience in Breast Cancer will be valued, but it is not mandatory. However, this area should be of keen interest to the fellow. Previous experience in clinical research will also be favorably considered. Since the fellow will be dealing directly with patients, the ability to communicate well in Spanish is mandatory. Written and spoken English are also required for interaction with study sponsors and investigators.
General description site location
The Vall d´Hebron University Hospital (HUVH), located within the Vall d´Hebron Barcelona Hospital Campus, is one of the largest and most important hospitals in Spain. HUVH’s Medical Oncology Department, directed by Dr. Josep Tabernero, centers on providing patient care of excellence and the bridging of cutting-edge basic and clinical research, with a determined focus on advancing translational oncology.
Organized into multidisciplinary and integrated teams, Vall d´Hebron physician-scientists closely collaborate with VHIO’s researchers. Translational science and clinical research are therefore tightly connected, accelerating the bench-bedside-bed cycle of knowledge.
Our Breast Cancer Unit performs early (phase I) and late clinical (phase II and III) studies with novel therapies against breast tumors. The main focus of our team is to translate novel targeted therapies and strategies to the clinic and test them in the treatment of breast tumors. Our Unit continues to grow from strength, gaining increased visibility and recognition across Europe and beyond.
At VHIO and HUVH, we believe in cementing strong collaborations with our other tumor-specific units, translational research laboratories, and our core technologies (including cancer genomics and molecular oncology).
In addition to our renowned expertise in early clinical drug development and clinical trials design, we also pioneer biomarker development (CTC, Pharmacodynamics, etc.), generate and develop patient-derived xenografts, and perform molecular analyses of tumors for treatment selection. Our institution provides all the essential facilities and technologies for translational research, with various groups focused on cancer-stem cells, cell-signaling, resistance to targeted therapies, genomics, and molecular oncology.
Potential candidates should send a CV, letter of motivation and the names and contact details of 2-3 references by email to: firstname.lastname@example.org, including the reference number 33/2019.
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge.
This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.
VHIO’s translation toward precision oncology: http://www.vhio.net
Vall d’Hebron Institute Oncology (VHIO) endorses the Requirements and Principles of the European Charter for Researchers, the Code of Conduct for the Recruitment of Researchers promoted by the European Commission and follows Equal Opportunities policies.
On 10th April 2018 VHIO was awarded the “HR Excellence in Research” logo. Our Institute was consequently granted permission to use the HR Excellence in Research Award logo as demonstration of its stimulating and favourable work environment in line with the Charter & Code.